Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. - Wikidata - wikimedia - TriplyDB

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.

http://www.wikidata.org/entity/Q42941758

about

Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease Mechanism of action of lenalidomide in hematological malignancies Thalidomide and thalidomide analogues for induction of remission in Crohn's disease Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study.Inhibition of endothelial activation: a new way to treat cerebral malaria?Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review Crosstalk between the heart and peripheral organs in heart failure Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents Thalidomide-induced teratogenesis: history and mechanisms Early experience with novel immunomodulators for cancer treatment The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity Epidemiological surveillance of birth defects compatible with thalidomide embryopathy in Brazil Embryonic mouse submandibular salivary gland morphogenesis and the TNF/TNF-R1 signal transduction pathway Intestinal secretory factor released by macrophages stimulated with Clostridium difficile toxin A: role of interleukin 1beta.Selective leukemic-cell killing by a novel functional class of thalidomide analogs Tumor necrosis factor-α synthesis inhibitor, 3,6'-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice Characterization of the mRNA ligands bound by the RNA binding protein hnRNP A2 utilizing a novel in vivo technique.Cancer cachexia: a therapeutic approach.Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.Anti-inflammatory thalidomide improves islet grafts survival and functions in a xenogenic environment Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.Update on potential medical treatments for encapsulating peritoneal sclerosis; human and experimental data Targeted therapy in melanoma.Inhibitory effects of phthalimide derivatives on the activity of the hepatic cytochrome P450 monooxygenases CYP2C9 and CYP2C19.Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC).Extracellular matrix molecules: potential targets in pharmacotherapy.Immunomodulating properties of the antibiotic novobiocin in human monocytes.Inhibition of tumor necrosis factor alpha alters resistance to Mycobacterium avium complex infection in mice.Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients.Immunomodulation by thalidomide and thalidomide analogues Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.Chronic graft-versus-host disease: is there an alternative to the conventional treatment?

P2860

Q21034132-8B6FA6DA-50E2-4E2F-A884-830E70227355 Q21089606-8149AB2D-BC63-4735-82A5-C6A40E855932 Q21093232-BFDD1054-ACA2-4590-8DBE-2025BE831C34 Q21198872-7004DC1A-3F44-4242-84A3-68EE701D5592 Q24241766-07ED0238-E113-4662-9DD7-42DEEF106E58 Q24634078-DB014512-E994-4C56-9C71-C7FE65C86384 Q24812750-8C3A8D39-96F4-48D7-9CDC-E304E15F67FF Q24814891-D3D83FCA-A7CE-4ADD-B2F5-94B1AFF65440 Q26743907-9AC45C53-0B69-4635-A175-E8332D771344 Q26766491-5E64F421-F96D-49E7-9E54-B0A473DA750D Q26770391-7620A232-323D-46D2-9A44-A3CE4999748D Q27001318-CE87F808-4F21-4D4D-9BC5-2545F359AE14 Q28075692-E573C5A2-CE19-408A-8383-421AE1DBF09C Q28085087-EF79973A-EAEB-42A8-8E7E-B749E211235F Q28241744-EBB86339-B455-403C-8DA7-85A732E8EDF7 Q28343837-716AB472-37C2-4759-AB92-4E7CB5A82417 Q28376504-4FDCB9BB-AF4F-4F0D-956B-BE7584B6596F Q28379160-6FEFF620-53CC-4693-A249-0CDB7440F345 Q28478928-F8A6E463-C867-4B85-9554-768A9103818F Q28506544-14C01CBA-903C-45AF-8559-C96FC4D6464E Q30453723-B08A3E11-2F82-4967-978E-394D2F87C57C Q30479632-954AA6D7-EE2E-4712-8DF9-4A6F673DE876 Q30520539-1AF18FE9-178E-4C89-8D96-F65FA9B758CA Q30860052-15B88E05-C00A-404E-A11E-F657B11C334B Q31791590-5DD9099A-0830-452D-94F3-24B89950E718 Q33238514-A6D2FE98-C240-4988-A792-4898A834A717 Q33406035-FD4DFC5A-F188-40A8-9B33-7D2883C58CB5 Q33484188-90F8D826-12A7-4E1B-9DE1-ED1104EE98BC Q33500473-E9535663-1937-4485-A33D-FF68AF1B9C3C Q33572005-47A8A565-96D2-4027-8855-C45DBBDD5B04 Q33573107-7559D1D6-BDB4-4592-A017-E00A34B581C6 Q33616683-9AB7DF8C-857E-42CB-BC9F-5CBF64E183F2 Q33655628-C0A4B3F7-574D-4DE0-98DC-3F0D192380CD Q33694487-F6D7B124-90B3-44DC-BE7D-7CC3B0152954 Q33694668-2353DB68-CABC-4749-8A0D-F18D7DF5D182 Q33696833-9043D53D-2CAC-44AB-9976-F390A0517D4D Q33760451-8FEFA332-B353-41A0-B562-2C609A725988 Q33782386-9B17E50F-DBBE-4863-83A2-B5E12E1273E3 Q33865839-D3426B33-B3F0-4566-A45C-AA9B76321163 Q33879944-140C146E-6169-40C2-B195-8E3BEAE841D7

P2860

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.

http://www.wikidata.org/entity/Q42941758

description

1993 nî lūn-bûn

@nan

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu

1993年论文

@zh

1993年论文

@zh-cn

name

Thalidomide exerts its inhibit ...... by enhancing mRNA degradation.

@en

Thalidomide exerts its inhibit ...... by enhancing mRNA degradation.

@nl

type

label

Thalidomide exerts its inhibit ...... by enhancing mRNA degradation.

@en

Thalidomide exerts its inhibit ...... by enhancing mRNA degradation.

@nl

prefLabel

Thalidomide exerts its inhibit ...... by enhancing mRNA degradation.

@en

Thalidomide exerts its inhibit ...... by enhancing mRNA degradation.

@nl

P1433

Q42941758-4666C893-D31B-436A-A2D5-2685226D3F33

P1476

Q42941758-82B6922A-C731-44E9-A305-2A694A5B0737

P2093

Q42941758-0014E233-A229-4497-B256-D0B8399FE1A5

Q42941758-3AFD91E4-ED40-4E1D-B8B0-850082CA05CE

Q42941758-793B2590-C989-47E4-B146-450CDB8D013B

Q42941758-B8606AF5-F1DB-40A4-BC26-2CD6FA8C7C8A

Q42941758-C80384D9-DE21-4BF9-8F47-8209B3C00CC5

Q42941758-CCDEF106-8C47-4F77-8BD6-BDCCA99F775E

P2860

Q42941758-1258863B-14A0-4F21-9E7D-91EB18542674

Q42941758-133E969C-8BEB-4F91-B06F-61AAEAB94D62

Q42941758-5C5BFBD4-E843-41AE-B739-2D80F0E1FAD1

Q42941758-6DDE6DB0-8E63-405D-89D4-A41FEDC3DC5E

Q42941758-775E9B65-DFBE-47D9-8D56-09CB1B9371DB

Q42941758-845F90D5-C86A-4522-9904-BD4275BB14CD

Q42941758-944F470E-FD22-4A41-9C8E-C086FD2FF3E4

Q42941758-9E1CD716-F73B-4621-B98B-3091AC32C44B

Q42941758-AC289741-7EF8-4394-BA11-966ED6AFC4E0

Q42941758-BA414C48-FB55-4589-8004-079B8F697C95

P304

Q42941758-46E495E4-94F9-434E-8932-C895F0BE7B1D

P31

Q42941758-352BB0AE-3032-4911-A488-B57B69F9977E

P356

Q42941758-33B1DD84-AE71-4CB1-884A-3E5E8F968CA5

P407

Q42941758-2F502642-4C0E-4711-8A79-98F24518D9B5

P433

Q42941758-3CCEDA6F-EE6A-4024-9393-A253C861C32A

P478

Q42941758-12C9A817-CF46-43D3-87EA-3C8346371E95

P577

Q42941758-8A3380F6-FC92-4A54-8CBD-F9DE89B1C557

P5875

Q42941758-1344AA50-64CF-4B58-BFA3-330E3A873152

P698

Q42941758-353E8C93-ED84-49C8-9F3A-384BF50F058E

P921

Q42941758-8FBEBF1C-E28F-48B3-9C65-51AB870D9D85

P932

Q42941758-E4691AEE-CFD3-420B-8B2F-AA289FF76804

P356

P1433

Journal of Experimental Medicine

P1476

Thalidomide exerts its inhibit ...... by enhancing mRNA degradation.

@en

P2093

A L Moreira

http://www.w3.org/2001/XMLSchema#string

A Zmuidzinas

http://www.w3.org/2001/XMLSchema#string

E P Sampaio

http://www.w3.org/2001/XMLSchema#string

G Kaplan

http://www.w3.org/2001/XMLSchema#string

K A Smith

http://www.w3.org/2001/XMLSchema#string

P Frindt

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed

Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states

A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation

Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism

Transcriptional and posttranscriptional regulation of tumor necrosis factor gene expression in human monocytes

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients

Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level

Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway.

Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia

P304

1675-1680

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.177.6.1675

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

177

http://www.w3.org/2001/XMLSchema#string

P577

1993-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14702001

http://www.w3.org/2001/XMLSchema#string

P698

8496685

http://www.w3.org/2001/XMLSchema#string

P921

P932

2191046

http://www.w3.org/2001/XMLSchema#string